Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Attorney: Expect PTO Director To Use ‘Discretion’ In New Patent Appeal Authority

Executive Summary

The US Supreme Court found that the role of administrative judges in patent review was unconstitutional but could be fixed by giving the PTO’s director more oversight, reinforcing the staying power of the patent appeals process.

You may also be interested in...

Lawyers Say Jackson’s Supreme Court Impact Could Be Felt On Administrative, Patent Cases

As confirmation hearings for Judge Ketanji Brown Jackson continue, MTI took a look at some of the core areas at stake. 

US Patent Office Updates Appeal Procedures In Wake Of Arthrex Decision

The interim process allows review of patent board verdicts by the director of the patent office either at the director’s initiative, or upon request of an involved party.

US Supreme Court Limits Estoppel Rule In Blow To PhRMA

Ruling keeps the principle of assignor estoppel in place, but restricts its use to situations where an inventor’s claims in court directly contradict those in the patent.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts